Latest CanVECTOR News
 

Annual incidence of

2/1000

population per year

Cost of VTE: at least

$600m

CAD a year

VTE recurrence

5-10%

per year

Chronic thromboembolic pulmonary hypertension 

3-4%

after PE

Pulmonary Embolism
leads to the hospitalization
or death of over

30,000

Canadians every year

VTE leads to significant

long-term
costs

in the form of chronic complications of VTE

Post-thrombotic syndrome

20-40%

after DVT

Adverse effects and

burden of anticoagulant therapy

Upcoming Events

Evidence Pearls on VTE

Evidence Pearls on VTE RSS Feed
Recurrence and mortality after first venous thromboembolism in a large population-based cohort.
Feb 28, 2017
Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.
Feb 28, 2017
Derivation and Internal Validation of a Clinical Prediction Tool for 30-Day Mortality in Lower Gastrointestinal Bleeding.
Feb 28, 2017
Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Feb 28, 2017
Clinical Selection Strategies to Identify Ischemic Stroke Patients With Large Anterior Vessel Occlusion: Results From SITS-ISTR (Safe Implementation of Thrombolysis in Stroke International Stroke Thrombolysis Registry).
Feb 28, 2017
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.
Feb 28, 2017
Recurrence and mortality after first venous thromboembolism in a large population-based cohort.
Feb 27, 2017
Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.
Feb 27, 2017
Derivation and Internal Validation of a Clinical Prediction Tool for 30-Day Mortality in Lower Gastrointestinal Bleeding.
Feb 27, 2017
Recurrence and mortality after first venous thromboembolism in a large population-based cohort.
Feb 26, 2017
Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.
Feb 26, 2017
Derivation and Internal Validation of a Clinical Prediction Tool for 30-Day Mortality in Lower Gastrointestinal Bleeding.
Feb 26, 2017
Recurrence and mortality after first venous thromboembolism in a large population-based cohort.
Feb 25, 2017
Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.
Feb 25, 2017
Derivation and Internal Validation of a Clinical Prediction Tool for 30-Day Mortality in Lower Gastrointestinal Bleeding.
Feb 25, 2017
Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.
Feb 24, 2017
Derivation and Internal Validation of a Clinical Prediction Tool for 30-Day Mortality in Lower Gastrointestinal Bleeding.
Feb 24, 2017
YAMATO Study (Tissue-Type Plasminogen Activator and Edaravone Combination Therapy).
Feb 24, 2017
Recurrence and mortality after first venous thromboembolism in a large population-based cohort.
Feb 24, 2017
Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.
Feb 23, 2017
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next

Twitter